Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30047280 | 0.89 | CA1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23856764 | 0.89 | CA1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3521744 | 0.86 | MAPT (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30954154 | 0.86 | MAPT (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31246136 | 0.86 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24436895 | 0.86 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3205636 | 0.86 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2472378 | 0.86 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL912906 | 0.84 | ALDH1A1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23088281 | 0.84 | MAPK1 (0.43) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242705-A1 | ESTER COMPOUND AND RESIN COMPOSITION | AJINOMOTO CO., INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-9120711-B2 | Carboxylation catalysts | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120711-B2 | Carboxylation catalysts | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130085276-A1 | CARBOXYLATION CATALYSTS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2013-04-04 | — | — | US | disclosed |
| US-20130085276-A1 | CARBOXYLATION CATALYSTS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2013-04-04 | — | — | US | disclosed |
| WO-2011154700-A1 | CARBOXYLATION CATALYSTS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2011-12-15 | — | — | WO | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085276-A1 | CARBOXYLATION CATALYSTS | CTH, ME3, CPN1 | CA12 21/4885CA1 117/4885CA2 102/4885 |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CA12 3023/4885CA1 1813/4885CA2 486/4885 |
| US-20230242705-A1 | ESTER COMPOUND AND RESIN COMPOSITION | AFF4, AFF1, AFF2 | CA12 4707/4885CA1 4135/4885CA2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.